CNIO researchers identify a new gene involved in the development of a rare endocrine tumour
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours and also the most hereditary form of all types of cancer. Researchers have for the first time linked mutations in the DLST gene with the development of such tumors. In addition to the importance of this finding for the future therapies, the discovery can broaden the number of families that may benefit from genetic counselling for prevention, detection and monitoring of these cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2019 Category: Cancer & Oncology Source Type: news
Screening for Neuroendocrine Tumors Is Recommended for NF1 Patients
A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Can Simple Clinical Factors Predict Metastatic Potential of Neuroendocrine Tumors?
Researchers have developed a clinical prediction model for the metastatic potential of pheochromocytoma and paraganglioma. (Source: CancerNetwork)
Source: CancerNetwork - August 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
FDA approves Progenics' drug for rare tumors
The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 31, 2018 Category: Pharmaceuticals Source Type: news
FDA Approves Azedra for Rare Adrenal Tumors
TUESDAY, July 31, 2018 -- Azedra (iobenguane) has been approved by the U.S. Food and Drug Administration to treat people 12 and older with rare adrenal gland tumors (pheochromocytoma or paraganglioma) that can ' t be surgically removed and have spread... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2018 Category: Pharmaceuticals Source Type: news
FDA approves first non-surgical treatment for 2 rare cancers
The Food and Drug Administration on Tuesday approved the first ever non-surgical treatment for the rare neuroendocrine cancers: pheochromocytoma and paraganglioma.
The approval for Azedra, a drug developed by Progenics Pharmacecuticals of Tarrytown, N.Y., was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania in Philadelphia.
“This is a true breakthrough," said Dr. Daniel A. Pryma, an associate professor of radiology and radiation… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 31, 2018 Category: American Health Authors: John George Source Type: news
Therapy for Rare Cancers receives FDA approval following trials at Penn's Abramson Cancer
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA (iobenguane I131). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2018 Category: Cancer & Oncology Source Type: news
FDA Approves Drug for Rare Adrenal Tumors
(MedPage Today) -- Iobenguane I 131 active in pheochromocytoma, paraganglioma (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 30, 2018 Category: Primary Care Source Type: news
Pheochromocytoma/Paraganglioma and Cancer Metabolism Pheochromocytoma/Paraganglioma and Cancer Metabolism
A better understanding of the metabolic pathophysiology in pheochromocytomas/paragangliomas may lead to more targeted treatment for these tumors.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Pheochromocytoma: A Genetic and Diagnostic Update Pheochromocytoma: A Genetic and Diagnostic Update
Improved diagnostic tools offer earlier and more accurate detection of pheochromocytomas and paragangliomas.Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Penn-led trial shows AZEDRA can be effective, safe for treatment of rare neuroendocrine tumors
(University of Pennsylvania School of Medicine) A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2018 Category: Cancer & Oncology Source Type: news
Cabozantinib Promising in Malignant Adrenal Gland Tumors
(MedPage Today) -- Longer PFS in patients with pheochromocytomas, paragangliomas (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 21, 2018 Category: Endocrinology Source Type: news
